Immunomodulatory therapy for sepsis: An update
dc.contributor.author | Christaki, Eirini | en |
dc.contributor.author | Anyfanti, Panagiota | en |
dc.contributor.author | Opal, Steven M. | en |
dc.creator | Christaki, Eirini | en |
dc.creator | Anyfanti, Panagiota | en |
dc.creator | Opal, Steven M. | en |
dc.date.accessioned | 2018-06-22T09:52:46Z | |
dc.date.available | 2018-06-22T09:52:46Z | |
dc.date.issued | 2011 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41498 | |
dc.description.abstract | Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis. © 2011 Expert Reviews Ltd. | en |
dc.language.iso | eng | en |
dc.source | Expert Review of Anti-Infective Therapy | en |
dc.subject | 3 (2 | |
dc.subject | 4 dimethoxybenzylidene)anabaseine | de |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Neurotoxicity | en |
dc.subject | Nephrotoxicity | en |
dc.subject | Review | en |
dc.subject | Antibiotic agent | en |
dc.subject | Disseminated intravascular clotting | en |
dc.subject | Unindexed drug | en |
dc.subject | Sepsis | en |
dc.subject | Intermethod comparison | en |
dc.subject | Antibodies | en |
dc.subject | Unclassified drug | en |
dc.subject | Cholinergic stimulation | en |
dc.subject | Drug megadose | en |
dc.subject | Immunologic factors | en |
dc.subject | Placebo | en |
dc.subject | Anti-inflammatory agents | en |
dc.subject | Hydroxymethylglutaryl coenzyme a reductase inhibitor | en |
dc.subject | Simvastatin | en |
dc.subject | Nonhuman | en |
dc.subject | Signal transduction | en |
dc.subject | Kidney dysfunction | en |
dc.subject | Pathophysiology | en |
dc.subject | Clinical trials as topic | en |
dc.subject | Blood clotting disorder | en |
dc.subject | Septic shock | en |
dc.subject | Apoptosis | en |
dc.subject | Immunity | en |
dc.subject | Innate | en |
dc.subject | Ventilator associated pneumonia | en |
dc.subject | Abdominal infection | en |
dc.subject | Acute kidney failure | en |
dc.subject | Acute lung injury | en |
dc.subject | Adaptive immunity | en |
dc.subject | Adenosine a2a receptor | en |
dc.subject | Adenosine a2a receptor agonist | en |
dc.subject | Advanced glycation end product receptor | en |
dc.subject | Animals | en |
dc.subject | Anti-bacterial agents | en |
dc.subject | Anticoagulant agent | en |
dc.subject | Anticoagulation | en |
dc.subject | Antiinflammatory agent | en |
dc.subject | Bacterial infection | en |
dc.subject | Bacterial infections | en |
dc.subject | Ceftriaxone | en |
dc.subject | Clarithromycin | en |
dc.subject | Community acquired pneumonia | en |
dc.subject | Complement activation | en |
dc.subject | Complement inhibitor | en |
dc.subject | Continuous hemofiltration | en |
dc.subject | Coupled plasma filtration adsorption | en |
dc.subject | Cytofab | en |
dc.subject | Device | en |
dc.subject | Didemethoxycurcumin | en |
dc.subject | Diet supplementation | en |
dc.subject | Endotoxemia | en |
dc.subject | Endotoxin | en |
dc.subject | Eritoran | en |
dc.subject | Gram-negative bacteria | en |
dc.subject | Hemoadsorption device | en |
dc.subject | High mobility group b1 protein antibody | en |
dc.subject | Hospital infection | en |
dc.subject | Hydrocortisone | en |
dc.subject | Immunity | en |
dc.subject | Immunomodulation | en |
dc.subject | Immunomodulatory strategies | en |
dc.subject | Immunoparalysis | en |
dc.subject | Immunostimulation | en |
dc.subject | Incyclinide | en |
dc.subject | Inflammation | en |
dc.subject | Inhibitor protein | en |
dc.subject | Inter alpha inhibitor protein | en |
dc.subject | Kidney injury | en |
dc.subject | Lactoferrin | en |
dc.subject | Liver injury | en |
dc.subject | Mice | en |
dc.subject | Multiple organ failure | en |
dc.subject | Oxiris | en |
dc.subject | Polymyxin b | en |
dc.subject | Protein antibody | en |
dc.subject | Protein c | en |
dc.subject | Protein targeting | en |
dc.subject | Renal replacement therapy | en |
dc.subject | Renal tubule assist device | en |
dc.subject | Resatorvid | en |
dc.subject | Respiratory failure | en |
dc.subject | Rosiglitazone | en |
dc.subject | Superantigen | en |
dc.subject | Talactoferrin | en |
dc.subject | Thymosin alpha1 | en |
dc.subject | Ulinastatin | en |
dc.title | Immunomodulatory therapy for sepsis: An update | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1586/eri.11.122 | |
dc.description.volume | 9 | |
dc.description.issue | 11 | |
dc.description.startingpage | 1013 | |
dc.description.endingpage | 1033 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Christaki, Eirini [0000-0002-8152-6367] | |
dc.contributor.orcid | Anyfanti, Panagiota [0000-0002-5658-4629] | |
dc.gnosis.orcid | 0000-0002-8152-6367 | |
dc.gnosis.orcid | 0000-0002-5658-4629 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |